TAF9 Antibody
| Code | Size | Price |
|---|
| PSI-7719-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7719-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Documents
Further Information
Additional Names:
TAF9 Antibody: TAF2G, TAFII31, TAFII32, MGC:5067, TAFII-31, TAFII-32, TAFIID32, STAF31/32, TAF2G, Transcription initiation factor TFIID subunit 9, RNA polymerase II TBP-associated factor subunit G
Application Note:
TAF9 antibody can be used for detection of TAF9 by Western blot at 1 - 2 μg/ml. Antibody can also be used for Immunohistochemistry at 5 μg/mL. For Immunoflorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
Initiation of transcription by RNA polymerase II is coordinated by the transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and the TBP-associated factors (TAFs). TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation (1). TAF9 is one of the smaller subunits of TFIID that binds to the basal transcription factor GTF2B as well as to several transcriptional activators such as p53 and VP16 (2).
Background References:
- Zawel L and Reinberg D. Advances in RNA polymerase II transcription. Curr. Opin. Cell Biol. 1992; 4:488-95.
- Klemm RD, Goodrich JA, Zhou S, et al. Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation. Proc. Natl. Acad. Sci. USA 1995; 92:5788-92.
Buffer:
TAF9 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%)
Immunogen:
TAF9 antibody was raised against a 17 amino acid peptide near the center of human TAF9.
The immunogen is located within amino acids 110 - 160 of TAF9.
The immunogen is located within amino acids 110 - 160 of TAF9.
NCBI Gene ID #:
6880
NCBI Official Name:
TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa
NCBI Official Symbol:
TAF9
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 29 kDa
Observed: 28 kDa
Observed: 28 kDa
Protein Accession #:
NP_003178
Protein GI Number:
4507351
Purification:
TAF9 antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
SPECIFICITY:
TAF9 antibody is human, mouse and rat reactive. Multiple isoforms of TAF9 are known to exist. TAF9 is predicted to not cross-react with other TAF family members.
Swissprot #:
Q16594
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | TAF9 Peptide | PSI-7719P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|